Publications by authors named "Emily Coates"

Claim this Profile
B
BCG Vaccination Potentially Modulates the Transcriptome of Infant CD4 T Cells in Addition to Age-Dependent Immune Ontogeny-Associated Changes.
Vidya Vijayan Karuvan Kandiyil, Eunchong Kang, Emily Coates, Portia Kamthunzi, Gerald Tegha

Vaccines (Basel)· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Virologic effects of broadly neutralizing antibodies VRC01LS and VRC07-523LS on chronic HIV-1 infection.
Myra Happe, Rebecca M Lynch, Carl J Fichtenbaum, Sonya L Heath, Susan L Koletar, Emily E Coates

JCI Insight· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 trial evaluating safety and pharmacokinetics of HIV-1 broadly neutralizing mAbs 10E8VLS and VRC07-523LS.
Seemal F Awan, Amarendra Pegu, Larisa Strom, Cristina A Carter, Cynthia S Hendel, Emily E Coates

JCI Insight· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials.
Myra Happe, Amelia R Hofstetter, Jing Wang, Galina V Yamshchikov, LaSonji A Holman, Emily E Coates

NPJ Vaccines· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial.
Betty Mwesigwa, Katherine V Houser, Amelia R Hofstetter, Ana M Ortega-Villa, Prossy Naluyima, Emily E Coates

Lancet Infect Dis· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIV vaccines induce CD8 T cells with low antigen receptor sensitivity.
Stephen A Migueles, Danielle M Nettere, Noah V Gavil, Lawrence T Wang, Sushila A Toulmin, Emily E Coates

Science· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chikungunya virus virus-like particle vaccine is well tolerated and immunogenic in chikungunya seropositive individuals.
James M McCarty, Lisa Bedell, Jason Mendy, Emily E Coates, Grace L Chen

Vaccine· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trial.
Kirsten E Lyke, Andrea A Berry, Kaitlin Mason, Azza H Idris, Mark O'Callahan, Emily E Coates

Lancet Infect Dis· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults.
Alicia T Widge, Amelia R Hofstetter, Katherine V Houser, Seemal F Awan, Grace L Chen, Emily E Coates

Sci Transl Med· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differences in HPV-specific antibody Fc-effector functions following Gardasil® and Cervarix® vaccination.
Vicky Roy, Wonyeong Jung, Caitlyn Linde, Emily Coates, Julie Ledgerwood

NPJ Vaccines· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial.
Melinda J Hamer, Katherine V Houser, Amelia R Hofstetter, Ana M Ortega-Villa, Christine Lee, Emily E Coates

Lancet· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial.
Emily E Coates, Srilatha Edupuganti, Grace L Chen, Myra Happe, Larisa Strom

Lancet Infect Dis· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria.
Richard L Wu, Azza H Idris, Nina M Berkowitz, Myra Happe, Martin R Gaudinski, Emily E Coates

N Engl J Med· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial.
Katherine V Houser, Martin R Gaudinski, Myra Happe, Sandeep Narpala, Raffaello Verardi, Emily E Coates

EClinicalMedicine· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial.
Joseph P Casazza, Evan M Cale, Sandeep Narpala, Galina V Yamshchikov, Emily E Coates

Nat Med· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial.
Katherine V Houser, Grace L Chen, Cristina Carter, Michelle C Crank, Thuy A Nguyen, Emily E Coates

Nat Med· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Monoclonal Antibody for Malaria Prevention.
Martin R Gaudinski, Nina M Berkowitz, Azza H Idris, Emily E Coates, LaSonji A Holman

N Engl J Med· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A sensitive method to quantify HIV-1 antibodies in mucosal samples.
Madhu Prabhakaran, Sandeep Narpala, Sarah F Andrews, Sarah O'Connell, Chien L Lin, Emily E Coates

J Immunol Methods· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Model Informed Development of VRC01 in Newborn Infants Using a Population Pharmacokinetics Approach.
Jerry Li, Mina Nikanjam, Coleen K Cunningham, Elizabeth J McFarland, Emily E Coates

Clin Pharmacol Ther· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial.
Grace L Chen, Emily E Coates, Sarah H Plummer, Cristina A Carter, Nina Berkowitz

JAMA· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activation Dynamics and Immunoglobulin Evolution of Pre-existing and Newly Generated Human Memory B cell Responses to Influenza Hemagglutinin.
Sarah F Andrews, Michael J Chambers, Chaim A Schramm, Jason Plyler, Julie E Raab, Emily Coates

Immunity· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study.
Martin R Gaudinski, Emily E Coates, Laura Novik, Alicia Widge, Katherine V Houser

Lancet· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults.
Martin R Gaudinski, Emily E Coates, Katherine V Houser, Grace L Chen, Galina Yamshchikov

PLoS Med· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preferential induction of cross-group influenza A hemagglutinin stem-specific memory B cells after H7N9 immunization in humans.
Sarah F Andrews, M Gordon Joyce, Michael J Chambers, Rebecca A Gillespie, Masaru Kanekiyo, Emily Coates

Sci Immunol· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial.
Adam D DeZure, Emily E Coates, Zonghui Hu, Galina V Yamshchikov, Kathryn L Zephir

NPJ Vaccines· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis